<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
<journal-title-group>
<journal-title>Translational Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">2158-3188</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29317596</article-id>
<article-id pub-id-type="pmc">5802496</article-id>
<article-id pub-id-type="publisher-id">61</article-id>
<article-id pub-id-type="doi">10.1038/s41398-017-0061-y</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rare loss of function mutations in <italic>N</italic>-methyl-<sc>d</sc>-aspartate glutamate receptors and their contributions to schizophrenia susceptibility</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Yanjie</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Yingni</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Takasaki</surname>
<given-names>Yuto</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chenyao</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kimura</surname>
<given-names>Hiroki</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xing</surname>
<given-names>Jingrui</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ishizuka</surname>
<given-names>Kanako</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toyama</surname>
<given-names>Miho</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kushima</surname>
<given-names>Itaru</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mori</surname>
<given-names>Daisuke</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arioka</surname>
<given-names>Yuko</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uno</surname>
<given-names>Yota</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shiino</surname>
<given-names>Tomoko</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nakamura</surname>
<given-names>Yukako</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Okada</surname>
<given-names>Takashi</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morikawa</surname>
<given-names>Mako</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ikeda</surname>
<given-names>Masashi</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iwata</surname>
<given-names>Nakao</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Okahisa</surname>
<given-names>Yuko</given-names>
</name>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Takaki</surname>
<given-names>Manabu</given-names>
</name>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sakamoto</surname>
<given-names>Shinji</given-names>
</name>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Someya</surname>
<given-names>Toshiyuki</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Egawa</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Usami</surname>
<given-names>Masahide</given-names>
</name>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kodaira</surname>
<given-names>Masaki</given-names>
</name>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yoshimi</surname>
<given-names>Akira</given-names>
</name>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6921-4566</contrib-id>
<name>
<surname>Oya-Ito</surname>
<given-names>Tomoko</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff13">13</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8982-4580</contrib-id>
<name>
<surname>Aleksic</surname>
<given-names>Branko</given-names>
</name>
<address>
<email>branko@med.nagoya-u.ac.jp</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ohno</surname>
<given-names>Kinji</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7360-4898</contrib-id>
<name>
<surname>Ozaki</surname>
<given-names>Norio</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution>Department of Psychiatry, </institution><institution>Nagoya University Graduate School of Medicine, </institution></institution-wrap>Nagoya, Japan </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution>Division of Neurogenetics, Center for Neurological Diseases and Cancer, </institution><institution>Nagoya University Graduate School of Medicine, </institution></institution-wrap>Nagoya, Japan </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1806 3501</institution-id><institution-id institution-id-type="GRID">grid.412467.2</institution-id><institution>Shengjing Hospital of China Medical University, </institution></institution-wrap>Shenyang, China </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution>Institute for Advanced Research, </institution><institution>Nagoya University, </institution></institution-wrap>Nagoya, Japan </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0943 978X</institution-id><institution-id institution-id-type="GRID">grid.27476.30</institution-id><institution>Brain and Mind Research Center, </institution><institution>Nagoya University, </institution></institution-wrap>Nagoya, Japan </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0569 8970</institution-id><institution-id institution-id-type="GRID">grid.437848.4</institution-id><institution>Center for Advanced Medicine and Clinical Research, </institution><institution>Nagoya University Hospital, </institution></institution-wrap>Nagoya, Japan </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8795 072X</institution-id><institution-id institution-id-type="GRID">grid.240206.2</institution-id><institution>Laboratory for Psychiatric and Molecular Neuroscience, </institution><institution>McLean Hospital, </institution></institution-wrap>Belmont, MA 02478 USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1761 798X</institution-id><institution-id institution-id-type="GRID">grid.256115.4</institution-id><institution>Department of Psychiatry, </institution><institution>Fujita Health University School of Medicine, </institution></institution-wrap>Toyoake, Japan </aff>
<aff id="Aff9"><label>9</label>Department of Neuropsychiatry Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0671 5144</institution-id><institution-id institution-id-type="GRID">grid.260975.f</institution-id><institution>Department of Psychiatry, </institution><institution>Niigata University Graduate School of Medical and Dental Sciences, </institution></institution-wrap>Niigata, Japan </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0489 0290</institution-id><institution-id institution-id-type="GRID">grid.45203.30</institution-id><institution>Department of Child and Adolescent Psychiatry Kohnodai Hospital, </institution><institution>National Center for Global Health and Medicine, </institution></institution-wrap>Tokyo, Japan </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.259879.8</institution-id><institution>Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, </institution><institution>Meijo University, </institution></institution-wrap>Nagoya, Japan </aff>
<aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.449197.6</institution-id><institution>Department of Nutrition, </institution><institution>Shubun University, </institution></institution-wrap>Ichinomiya, Japan </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>10</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>10</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>8</volume>
<elocation-id>12</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">In schizophrenia (SCZ) and autism spectrum disorder (ASD), the dysregulation of glutamate transmission through <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors (NMDARs) has been implicated as a potential etiological mechanism. Previous studies have accumulated evidence supporting NMDAR-encoding genes' role in etiology of SCZ and ASD. We performed a screening study for exonic regions of <italic>GRIN1</italic>, <italic>GRIN2A</italic>, <italic>GRIN2C</italic>, <italic>GRIN2D</italic>, <italic>GRIN3A</italic>, and <italic>GRIN3B</italic>, which encode NMDAR subunits, in 562 participates (370 SCZ and 192 ASD). Forty rare variants were identified including 38 missense, 1 frameshift mutation in <italic>GRIN2C</italic> and 1 splice site mutation in <italic>GRIN2D</italic>. We conducted in silico analysis for all variants and detected seven missense variants with deleterious prediction. De novo analysis was conducted if pedigree samples were available. The splice site mutation in <italic>GRIN2D</italic> is predicted to result in intron retention by minigene assay. Furthermore, the frameshift mutation in <italic>GRIN2C</italic> and splice site mutation in <italic>GRIN2D</italic> were genotyped in an independent sample set comprising 1877 SCZ cases, 382 ASD cases, and 2040 controls. Both of them were revealed to be singleton. Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p id="Par2">Schizophrenia (SCZ)and autism spectrum disorder (ASD) both have been implied to a high heritability and a strong genetic basis<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. SCZ is a common, serious mental disorder which affects nearly 1% people of the world<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Twin studies estimated its heritability to be up to 80%<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. ASD is a range of heterogeneous neurodevelopmental conditions which has early-onset deficiency in social communication and interactions, and also behavioral functioning<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. The etiology of ASD is strongly impacted by genetics, with heritability estimates of 56–95%<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p>
<p id="Par3">Glutamate is one of the most important excitatory neurotransmitter in synapse systems and 40% of all synapses<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> are exploiting it. Glutamate is involved in many central nervous system processes and basic neuronal functions<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Thus, abnormal glutamatergic neurotransmission could be a point of convergence to describe the neurocognitive deficits and feature of symptoms presented in nervous system diseases<sup><xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR10">10</xref></sup>. <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors (NMDARs) indicated to be one of the most common glutamate receptors. The pathology of anti-NMDAR encephalitis implies that abnormalities in glutamatergic signaling can result in cognitive impairment, mood changes, and impairment of behavior, which are the symptoms often observed in SCZ/ASD patients<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. To date, NMDAR subunits have three main family members that have been identified: NR1, NR2, and NR3. Those subunits are encoded by <italic>GRIN1</italic>, <italic>GRIN2A</italic>, <italic>GRIN2B</italic>, <italic>GRIN2C</italic>, <italic>GRIN2D</italic>, <italic>GRIN3A</italic>, and <italic>GRIN3B</italic>
<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>, respectively.</p>
<p id="Par4">Resequencing studies suggested that <italic>GRIN2A</italic> might be a candidate gene for autism and SCZ<sup><xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref></sup> A genomic data analysis study suggests <italic>GRIN2C</italic> as another SCZ candidate gene<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. An exome sequencing study which sequenced all <italic>GRIN</italic> genes in SCZ and ASD cases, detected de novo variants in <italic>GRIN2B</italic> and <italic>GRIN2A</italic> and loss-of-function (LoF) variants in <italic>GRIN2C</italic>, <italic>GRIN3A</italic>, and <italic>GRIN3B</italic>
<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Novel de novo microduplications in 19q13, where <italic>GRIN2D</italic> resides in, were identified in ASD<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. In addition, a study that identified significant association between <italic>GRIN3B</italic> and mismatch negativity (MMN) also deserves attention, as decreasing MMN was suggested to be correlated with the pathogenesis of SCZ<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Furthermore, in mouse studies, <italic>GRIN2A</italic>-null mice exhibit some SCZ-like symptoms<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Studies with <italic>GRIN2C</italic> knockout mice pointed out NR2C receptors might play a potential role in associative and executive learning<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Further mice studies showed that NR2D subunit incorporates into the NMDARs that mediate excitatory synaptic transmission onto interneurons and influence interneuron function and signal processing<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Altogether, these findings suggested the importance of <italic>GRIN</italic> genes in the pathogenesis of SCZ and ASD.</p>
<p id="Par5">Recently, there have been accumulating evidence supporting a role of rare variants in mental disorders causation<sup><xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR27">27</xref></sup>, especially rare LoF (nonsense, splice site or frameshift) variants<sup><xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR30">30</xref></sup>. While frameshift and nonsense mutations are clearly to be LoF, the effect of splice site mutation remains to be defined. To our knowledge, till now, previous papers have not put their attention on <italic>GRIN gene</italic>s splice site mutation in cases of neuropsychiatric disorders. In previous work<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, we sequenced <italic>GRIN2B</italic> in SCZ and ASD, identifying five rare missense mutations. In present study, we performed a mutation screening study for the exonic regions of <italic>GRIN1</italic>,<italic> GRIN2A</italic>, <italic>GRIN2C</italic>,<italic> GRIN2D</italic>, <italic>GRIN3A</italic>, and <italic>GRIN3B</italic>. We assessed the functional impact of splice site mutation by minigene assay, and performed genotyping for LoF mutations in a large sample set.</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>Methods</title>
<sec id="Sec3">
<title>Samples</title>
<p id="Par6">In this study, two independent sample groups were designed (Table <xref ref-type="table" rid="Tab1">1</xref>). The first one, which included 370 SCZ and 192 ASD patients, resequencing for mutation discovery. The second one, with 1877 SCZ cases, 382 ASD cases, and 2040 healthy controls, was used for genotyping of selected mutations identified in the first step. All participates in our study are ethnically Japanese, live on the mainland of Japan. The Hospital of Nagoya University and its co-institutes (Toyama University, Niigata University, Fujita Health University) and co-hospital (Kohnodai Hospital) recruited all the participates. Patients included in the study were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for SCZ or ASD. Controls were recruited from ordinary people and were evaluated with an unstructured interview to ensure that they never suffer from psychiatric disorders, both personal and family history. We explained our study to all participants both verbally and in writing. In addition, if individuals had no capacity to do this alone, their parents or other family members were required to complete written informed consent. The study was supported by Ethics Committees of the Nagoya University Graduate School of Medicine and co-institutes and co-hospital.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Profiles of samples in the small set for resequencing and the large set for association analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="2">Resequencing</th><th colspan="2">Association analysis</th><th></th></tr><tr><th></th><th>SCZ</th><th>ASD</th><th>SCZ</th><th>ASD</th><th>Controls</th></tr></thead><tbody><tr><td>Total</td><td>370</td><td>192</td><td>1877</td><td>382</td><td>2040</td></tr><tr><td>Male</td><td>196 (52.97%)</td><td>149 (77.60%)</td><td>1027 (54.71%)</td><td>297 (77.75%)</td><td>998 (48.92%)</td></tr><tr><td>Female</td><td>174 (47.03%)</td><td>43 (22.40%)</td><td>850 (45.29%)</td><td>85 (22.25%)</td><td>1042 (51.08%)</td></tr><tr><td>Mean age (years)</td><td>49.73 ± 14.75</td><td>16.34 ± 8.36</td><td>46.87 ± 15.35</td><td>19.61 ± 10.71</td><td>46.89 ± 14.61</td></tr></tbody></table><table-wrap-foot><p>
<italic>SCZ</italic> schizophrenia; <italic>ASD</italic> autism spectrum disorders,</p><p>age at recruitment</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec4">
<title>Sequencing and data collection</title>
<p id="Par7">We extracted genomic DNA from whole peripheral blood or saliva by a standard protocol. For covering coding regions of <italic>GRIN1</italic>, <italic>GRIN2A</italic>, <italic>GRIN2C</italic>, <italic>GRIN2D</italic>, <italic>GRIN3A</italic>, and <italic>GRIN3B</italic> (human reference sequence NCBI (build 37)), we designed custom amplification primers by FastPCR (PrimerDigital Ltd, Helsinki, Finland) and NCBI Primer-BLAST. The Ion Library Equalizer Kit Adapters and Ion AmpliSeq Library Kits 2.0 (Thermo Fisher Scientific, Foster City, CA, USA) were used for amplification and equalization. Then Ion Xpress Barcode was used to collect the amplified sequence. We used Ion Torrent PGM™ (Thermo Fisher Scientific) to sequence the products by next-generation sequencing technology. Then we performed an analysis for the resulting data using Ingenuity Variant Analysis (Qiagen Ltd, Hilden, Germany).</p>
</sec>
<sec id="Sec5">
<title>Filter conditions and in silico analysis</title>
<p id="Par8">Rare (minor allele frequency &lt; 1%), nonsynonymous variants, which was located on the functional domain, under the Human Protein Reference Database (<ext-link ext-link-type="uri" xlink:href="http://www.hprd.org">http://www.hprd.org</ext-link>), EMBL-EBI (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/">https://www.ebi.ac.uk/</ext-link>), and the existing literatures (Table <xref ref-type="table" rid="Tab2">2</xref>), were selected from the original data for further analysis. These filtered variants were then sequenced for confirming their reliability by Sanger method in a 3130XL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Details of discovered rare mutations and in silico analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><th>a</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></tr><tr><th>Chromosome</th><th>Position</th><th>Reference allele</th><th>Sample allele</th><th>Gene symbol</th><th>Phenotype</th><th>Protein variant</th><th>dbSNP ID</th><th>1000 Genomes frequency</th><th>NHLBI ESP frequency</th><th>HGVD frequency</th><th>iJGVD frequency</th><th>SIFT function prediction</th><th>PolyPhen-2 function prediction</th><th>MUTATIONTASTER function prediction</th><th>PRIMATE phcons</th><th>Primate phylop</th><th>Pedigree analysis</th></tr></thead><tbody><tr><td>9</td><td>14,0052,907</td><td>G</td><td>A</td><td>
<italic>GRIN1</italic>
</td><td>SCZ</td><td>p.A349T; p.A370T</td><td>Rs148008303</td><td>0.0002</td><td>0.00006</td><td></td><td></td><td>Damaging</td><td>Possibly Damaging</td><td>disease causing</td><td>0.993</td><td>0.557</td><td></td></tr><tr><td>16</td><td>9,858,015</td><td>T</td><td>C</td><td>
<italic>GRIN2A</italic>
</td><td>SCZ</td><td>p.H1129R</td><td></td><td></td><td>0.000016</td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.074</td><td>0.525</td><td></td></tr><tr><td>16</td><td>9,858,403</td><td>C</td><td>T</td><td>
<italic>GRIN2A</italic>
</td><td>ASD</td><td>p.V1000M</td><td></td><td></td><td></td><td></td><td></td><td>Tolerated</td><td>Possibly Damaging</td><td>disease causing</td><td>0.959</td><td>0.651</td><td>inherited</td></tr><tr><td>16</td><td>9,858,511</td><td>G</td><td>C</td><td>
<italic>GRIN2A</italic>
</td><td>SCZ</td><td>p.Q964E</td><td></td><td></td><td>0.000032</td><td></td><td>0.0005</td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.983</td><td>0.651</td><td></td></tr><tr><td>16</td><td>9,858,751</td><td>C</td><td>T</td><td>
<italic>GRIN2A</italic>
</td><td>SCZ</td><td>p.D884N</td><td>Rs777684328</td><td>0.00002</td><td></td><td>0.0009</td><td>Damaging</td><td>Possibly Damaging</td><td>disease causing</td><td>0.994</td><td>0.651</td><td></td><td></td></tr><tr><td>16</td><td>9,858,774</td><td>A</td><td>G</td><td>
<italic>GRIN2A</italic>
</td><td>ASD</td><td>p.I876T</td><td>Rs199784503</td><td>0.0004</td><td>0.0003</td><td></td><td>0.0023</td><td>Tolerated</td><td>Probably Damaging</td><td>disease causing</td><td>0.965</td><td>0.53</td><td>inherited</td></tr><tr><td>16</td><td>9,862,785</td><td>G</td><td>A</td><td>
<italic>GRIN2A</italic>
</td><td>ASD</td><td>p.L840F</td><td>Rs371352783</td><td>0.00002</td><td></td><td></td><td>Damaging</td><td>Possibly Damaging</td><td>disease causing</td><td>0.997</td><td>0.559</td><td>inherited</td><td></td></tr><tr><td>16</td><td>9,927,969</td><td>T</td><td>G</td><td>
<italic>GRIN2A</italic>
</td><td>ASD</td><td>p.K590N</td><td></td><td></td><td>0.000033</td><td></td><td>0.0005</td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.985</td><td>0.525</td><td></td></tr><tr><td>16</td><td>9,943,618</td><td>T</td><td>G</td><td>
<italic>GRIN2A</italic>
</td><td>ASD</td><td>p.K441N</td><td></td><td></td><td></td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.995</td><td>0.525</td><td></td></tr><tr><td>16</td><td>10,032,377</td><td>G</td><td>A</td><td>
<italic>GRIN2A</italic>
</td><td>SCZ</td><td>p.A149V</td><td></td><td>0.04</td><td></td><td></td><td>0.0009</td><td>Tolerated</td><td>Probably Damaging</td><td>disease causing</td><td>0.956</td><td>0.559</td><td></td></tr><tr><td>16</td><td>10,032,405</td><td>G</td><td>C</td><td>
<italic>GRIN2A</italic>
</td><td>SCZ</td><td>p.P140A</td><td></td><td></td><td>0.000008</td><td></td><td>0.0009</td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.932</td><td>0.559</td><td></td></tr><tr><td>17</td><td>72,839,530</td><td>C</td><td>T</td><td>
<italic>GRIN2C</italic>
</td><td>ASD</td><td>p.A916T</td><td></td><td></td><td></td><td>0.0014</td><td>0.0005</td><td>Tolerated</td><td>Probably Damaging</td><td>disease causing</td><td>0.981</td><td>0.45</td><td>inherited</td></tr><tr><td>17</td><td>72,846,024</td><td>C</td><td>T</td><td>
<italic>GRIN2C</italic>
</td><td>ASD</td><td>p.E514K</td><td></td><td></td><td></td><td>0.0017</td><td></td><td>Tolerated</td><td>Possibly Damaging</td><td>disease causing</td><td>0.992</td><td>0.486</td><td></td></tr><tr><td>17</td><td>72,846,374</td><td>G</td><td>A</td><td>
<italic>GRIN2C</italic>
</td><td>SCZ</td><td>p.R488C</td><td>Rs186790306</td><td>0.0014</td><td>0.00007</td><td></td><td></td><td>Damaging</td><td>Probably Damaging</td><td>disease causing</td><td>0.994</td><td>0.486</td><td></td></tr><tr><td>17</td><td>72,846,483</td><td>C</td><td>G</td><td>
<italic>GRIN2C</italic>
</td><td>SCZ</td><td>p.K451N</td><td></td><td></td><td></td><td></td><td></td><td>Damaging</td><td>Probably Damaging</td><td>disease causing</td><td>0.722</td><td>−0.347</td><td></td></tr><tr><td>17</td><td>72,846,705</td><td>G</td><td>A</td><td>
<italic>GRIN2C</italic>
</td><td>ASD</td><td>p.H439Y</td><td></td><td></td><td></td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.015</td><td>0.557</td><td>inherited</td></tr><tr><td>17</td><td>72,846,800</td><td>G</td><td>A</td><td>
<italic>GRIN2C</italic>
</td><td>SCZ</td><td>p.T407M</td><td>Rs536926397</td><td>0.0002</td><td>0.00002</td><td></td><td></td><td>Damaging</td><td>Probably Damaging</td><td>disease causing</td><td>0.318</td><td>0.55</td><td></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th>b</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></tr><tr><th>Chromosome</th><th>Position</th><th>Reference allele</th><th>Sample allele</th><th>Gene symbol</th><th>Phenotype</th><th>Protein cariant</th><th>dbSNP ID</th><th>1000 Genomes frequency</th><th>NHLBI ESP Frequency</th><th>HGVD Frequency</th><th>iJGVD Frequency</th><th>SIFT Function Prediction</th><th>PolyPhen-2 Function Prediction</th><th>MUTATIONTASTER Function Prediction</th><th>Primate PhCons</th><th>primate PhyloP</th><th>Pedigree analysis</th></tr></thead><tbody><tr><td>17</td><td>72,850,836</td><td>GGGG</td><td></td><td>
<italic>GRIN2C</italic>
</td><td>SCZ</td><td>p.P132fs*59</td><td></td><td></td><td></td><td></td><td>NA</td><td>NA</td><td>disease causing</td><td>0.477</td><td>0.645</td><td></td><td></td></tr><tr><td>17</td><td>72,850,840</td><td>G</td><td>A</td><td>
<italic>GRIN2C</italic>
</td><td>ASD</td><td>p.T131I</td><td>Rs780165386</td><td>0.000009</td><td></td><td></td><td>Damaging</td><td>Possibly Damaging</td><td>disease causing</td><td>0.401</td><td>−0.176</td><td></td><td></td></tr><tr><td>17</td><td>72,851,093</td><td>G</td><td>A</td><td>
<italic>GRIN2C</italic>
</td><td>SCZ</td><td>p.R47C</td><td>Rs776102062</td><td>0.00003</td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.867</td><td>−0.276</td><td></td><td></td></tr><tr><td>19</td><td>48,908,432</td><td>G</td><td>A</td><td>
<italic>GRIN2D</italic>
</td><td>ASD</td><td>p.G303R</td><td></td><td></td><td></td><td></td><td></td><td>Tolerated</td><td>Possibly Damaging</td><td>disease causing</td><td>0.401</td><td>0.557</td><td>inherited</td></tr><tr><td>19</td><td>48,908,447</td><td>C</td><td>T</td><td>
<italic>GRIN2D</italic>
</td><td>SCZ</td><td>p.R308C</td><td>Rs746751166</td><td>0.00002</td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.989</td><td>0.557</td><td></td><td></td></tr><tr><td>19</td><td>48,917,841</td><td>G</td><td>A</td><td>
<italic>GRIN2D</italic>
</td><td>SCZ</td><td>p.S471N</td><td></td><td></td><td></td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.992</td><td>0.651</td><td></td></tr><tr><td>19</td><td>48,918,122</td><td>C</td><td>A</td><td>
<italic>GRIN2D</italic>
</td><td>SCZ</td><td>p.P472T</td><td></td><td></td><td></td><td></td><td></td><td>Tolerated</td><td>Possibly Damaging</td><td>disease causing</td><td>0.94</td><td>0.651</td><td></td></tr><tr><td>19</td><td>48,945,428</td><td>G</td><td>A</td><td>
<italic>GRIN2D</italic>
</td><td>SCZ</td><td>p.R821Q</td><td>Rs767410370</td><td>0.000008</td><td></td><td></td><td>Tolerated</td><td>Probably Damaging</td><td>disease causing</td><td>0.966</td><td>0.451</td><td></td><td></td></tr><tr><td>19</td><td>48,947,106</td><td>C</td><td>T</td><td>
<italic>GRIN2D</italic>
</td><td>ASD</td><td>p.P1308L</td><td></td><td></td><td></td><td>0.0049</td><td>0.0028</td><td>deleterious</td><td>NA</td><td>disease causing</td><td>0.038</td><td>0.466</td><td></td></tr><tr><td>9</td><td>104,375,732</td><td>C</td><td>A</td><td>
<italic>GRIN3A</italic>
</td><td>ASD</td><td>p.G898W</td><td></td><td></td><td></td><td></td><td>0.0005</td><td>Damaging</td><td>Probably Damaging</td><td>disease causing</td><td>0.948</td><td>0.651</td><td></td></tr><tr><td>9</td><td>104,433,232</td><td>T</td><td>C</td><td>
<italic>GRIN3A</italic>
</td><td>ASD/SCZ</td><td>p.K488E</td><td>Rs189425146 0.0042</td><td>0.42</td><td>0.0009</td><td></td><td>0.0009</td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.985</td><td>0.53</td><td>inherited</td></tr><tr><td>9</td><td>104,449,017</td><td>C</td><td>T</td><td>
<italic>GRIN3A</italic>
</td><td>SCZ</td><td>p.V389I</td><td>Rs200120504</td><td>0.0002</td><td></td><td>0.0005</td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.99</td><td>0.559</td><td></td><td></td></tr><tr><td>9</td><td>104,449,173</td><td>G</td><td>A</td><td>
<italic>GRIN3A</italic>
</td><td>ASD/SCZ</td><td>p.R337W</td><td>Rs773593066</td><td>0.00008</td><td>0.0017</td><td>0.0009</td><td>Damaging</td><td>Possibly Damaging</td><td>disease causing</td><td>0.971</td><td>0.559</td><td>inherited</td><td></td></tr><tr><td>9</td><td>104,499,853</td><td>G</td><td>T</td><td>
<italic>GRIN3A</italic>
</td><td>ASD</td><td>p.R137S</td><td>Rs769491656</td><td></td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.988</td><td>0.651</td><td>inherited</td><td></td></tr><tr><td>19</td><td>1,003,244</td><td>C</td><td>T</td><td>
<italic>GRIN3B</italic>
</td><td>SCZ</td><td>p.T181I</td><td>Rs540094501</td><td>0.0004</td><td>0.0002</td><td>0.0087</td><td>0.2924</td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.002</td><td>−0.397</td><td></td></tr><tr><td>19</td><td>1,003,255</td><td>G</td><td>A</td><td>
<italic>GRIN3B</italic>
</td><td>SCZ</td><td>p.G185S</td><td>Rs575985258</td><td>0.001</td><td>0.0006</td><td>0.0005</td><td>0.0005</td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.016</td><td>−0.397</td><td></td></tr><tr><td>19</td><td>1,003,721</td><td>G</td><td>A</td><td>
<italic>GRIN3B</italic>
</td><td>SCZ</td><td>p.R340Q</td><td>Rs577413695</td><td>0.0002</td><td></td><td></td><td></td><td>Tolerated</td><td>Benign</td><td>disease causing</td><td>0.652</td><td>0.459</td><td></td></tr><tr><td>19</td><td>1,004,573</td><td>G</td><td>A</td><td>
<italic>GRIN3B</italic>
</td><td>SCZ</td><td>p.G358D</td><td>Rs75047944</td><td>0.0006</td><td>0.0001</td><td>0.0044</td><td>0.0089</td><td>Damaging</td><td>Probably Damaging</td><td>disease causing</td><td>0.054</td><td>−0.524</td><td></td></tr><tr><td>19</td><td>1,004,998</td><td>G</td><td>A</td><td>
<italic>GRIN3B</italic>
</td><td>ASD/SCZ</td><td>p.V500M</td><td>Rs377572345</td><td>0.0001</td><td>0.0014</td><td></td><td>Damaging</td><td>Probably Damaging</td><td>disease causing</td><td>0.192</td><td>0.48</td><td></td><td></td></tr><tr><td>19</td><td>1,005,098</td><td>G</td><td>T</td><td>
<italic>GRIN3B</italic>
</td><td>ASD</td><td>p.S533I</td><td>Rs200427089</td><td>0.0004</td><td>0.0002</td><td>0.0036</td><td>0.002</td><td>Damaging</td><td>Possibly Damaging</td><td>disease causing</td><td>0.933</td><td>0.48</td><td>inherited</td></tr><tr><td>19</td><td>1,005,209</td><td>T</td><td>A</td><td>
<italic>GRIN3B</italic>
</td><td>SCZ</td><td>p.M570K</td><td>Rs750803476</td><td>0.0001</td><td></td><td></td><td>Tolerated</td><td>Possibly Damaging</td><td>disease causing</td><td>0.863</td><td>0.393</td><td></td><td></td></tr><tr><td>19</td><td>1,005,523</td><td>G</td><td>A</td><td>
<italic>GRIN3B</italic>
</td><td>SCZ</td><td>p.E675K</td><td>Rs759438437</td><td>0.000009</td><td>0.0005</td><td></td><td>Damaging</td><td>Probably Damaging</td><td>disease causing</td><td>0.026</td><td>−0.863</td><td></td><td></td></tr><tr><td>19</td><td>1,008,142</td><td>A</td><td>G</td><td>
<italic>GRIN3B</italic>
</td><td>SCZ</td><td>p.Y773C</td><td></td><td></td><td></td><td>0.0009</td><td></td><td>Tolerated</td><td>Probably Damaging</td><td>disease causing</td><td>0.081</td><td>−0.897</td><td></td></tr></tbody></table><table-wrap-foot><p>Genomic position is based on GRCh37/hg19</p><p>
<italic>SNV</italic>single-nucleotide variant</p><p>
<italic>dbSNP</italic>: dbSNP build 139 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/">http://www.ncbi.nlm.nih.gov/projects/SNP/</ext-link>); <italic>1000 Genomes</italic> the 1000 Genomes Project (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org">http://www.1000genomes.org</ext-link>), <italic>NHLBI</italic> Exome Aggregation Consortium (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>), <italic>HGVD</italic> the Human Genetic Variation Database (<ext-link ext-link-type="uri" xlink:href="http://www.genome.med.kyoto-u.ac.jp/SnpDB/">http://www.genome.med.kyoto-u.ac.jp/SnpDB/</ext-link>), <italic>iJGVD</italic> Integrative Japanese Genome Variation (<ext-link ext-link-type="uri" xlink:href="https://ijgvd.megabank.tohoku.ac.jp/">https://ijgvd.megabank.tohoku.ac.jp/</ext-link>)</p><p>SIFT (<ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org/">http://sift.jcvi.org/</ext-link>), <italic>PolyPhen-2</italic> polymorphism phenotyping v.2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/index.shtml">http://genetics.bwh.harvard.edu/pph2/index.shtml</ext-link>). MUTATIONTASTER (<ext-link ext-link-type="uri" xlink:href="http://www.mutationtaster.org/">http://www.mutationtaster.org/</ext-link>). PhastCons conservation score (<ext-link ext-link-type="uri" xlink:href="http://compgen.cshl.edu/phast/phastCons-HOWTO.html">http://compgen.cshl.edu/phast/phastCons-HOWTO.html</ext-link>): produces predictions of discrete conserved elements</p></table-wrap-foot></table-wrap>
</p>
<p id="Par9">We further analyzed those variants with the following methods: (1) we explored whether they were registered in the NCBI dbSNP database (build 137) (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/">http://www.ncbi.nlm.nih.gov/SNP/</ext-link>), the Exome Aggregation Consortium (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>), the 1000 Genomes Project (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org/">http://www.1000genomes.org/</ext-link>), the Integrative Japanese Genome Variation (<ext-link ext-link-type="uri" xlink:href="https://ijgvd.megabank.tohoku.ac.jp/">https://ijgvd.megabank.tohoku.ac.jp/</ext-link>), or the Human Genetic Variation Database (<ext-link ext-link-type="uri" xlink:href="http://www.hgvd.genome.med.kyoto-u.ac.jp/index.html">http://www.hgvd.genome.med.kyoto-u.ac.jp/index.html</ext-link>); (2) we looked for a possible impact of amino acid substitutions as predicted by PolyPhen-2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, SIFT (<ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org/">http://sift.jcvi.org/</ext-link>)<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, and MUTATIONTASTER (<ext-link ext-link-type="uri" xlink:href="http://www.mutationtaster.org/">http://www.mutationtaster.org/</ext-link>)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>; (3) we investigated the conservation status using the PhastCons conservation score and PhyloP scores using the single-nucleotide variants scoring tool Combined Annotation Dependent Depletion<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> (Table <xref ref-type="table" rid="Tab2">2</xref>).</p>
</sec>
<sec id="Sec6">
<title>Splicing in silico analysis</title>
<p id="Par10">For the splice site mutation, for predicting splicing outcomes of mutations leading to 5′-splice site splicing defects, we performed the following in silico analysis: SD-Score<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, human splice finder<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, and MaxEntScan<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> (Table <xref ref-type="table" rid="Tab3">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Details of loss-of-function mutations identified in NMDAR subunits</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Position</th><th>Translation impact</th><th>Exon</th><th>Gene name</th><th>Nucleotide variant</th><th>Protein variant</th><th>Phenotype</th><th>Case sample with variant</th><th colspan="4">Frequency in database</th><th colspan="3">In sili<italic>co</italic> analysis for amino acid substitution</th><th colspan="3">Splice site in sili<italic>co</italic> analysis</th></tr><tr><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>1000 Genomes</th><th>NHLBI</th><th>HGVD</th><th>iJGVD</th><th>PolyPhen-2</th><th>SIFT</th><th>MUTATIONTASTER</th><th>SD-Score</th><th>Human splice finder</th><th>MAXENT</th></tr></thead><tbody><tr><td>17:72,850,836</td><td>Frameshift</td><td>2</td><td>
<italic>GRIN2C</italic>
</td><td>delGGGG</td><td>P132FsX192</td><td>SCZ</td><td>1/370</td><td>Not registered</td><td>Not registered</td><td>Not registered</td><td>Not registered</td><td>NA</td><td>NA</td><td>Disease causing</td><td></td><td></td><td></td></tr><tr><td>19:48,917,841</td><td>Splice site</td><td>5</td><td>
<italic>GRIN2D</italic>
</td><td>G&gt;A</td><td>S471X472</td><td>SCZ</td><td>1/370</td><td>Not registered</td><td>Not registered</td><td>Not registered</td><td>Not registered</td><td>Benign</td><td>Tolerated</td><td>Disease causing</td><td>Aberrant</td><td>Most probably affecting splicing</td><td>−1.87</td></tr></tbody></table><table-wrap-foot><p>
<italic>NA</italic> not applicable; genomic position is based on GRCh37/hg19. Amino acid change based on NCBI reference sequence NP_060138.1</p><p>D-Score (<ext-link ext-link-type="uri" xlink:href="http://www.med.nagoya-u.ac.jp/neurogenetics/SD_Score/sd_score.html">http://www.med.nagoya-u.ac.jp/neurogenetics/SD_Score/sd_score.html</ext-link>), human splice finder (<ext-link ext-link-type="uri" xlink:href="http://www.umd.be/HSF3/">http://www.umd.be/HSF3/</ext-link>); MaxEntScan (<ext-link ext-link-type="uri" xlink:href="http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html">http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html</ext-link>)</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec7">
<title>Construction of the plasmid containing the <italic>GRIN2D</italic> minigene</title>
<p id="Par11">We constructed the c.1412G&gt;A-<italic>GRIN2D</italic> minigene in the pcDNA3.1(+) vector by amplifying the 5′-end of exon 4 (starting from the second nucleotide of exon 4 to retain the normal open reading frame) to the 3′-end of exon 6 of <italic>GRIN2D</italic> from genomic DNA, which was extracted from the c.1412G&gt;A-<italic>GRIN2D</italic> mutant sample and one healthy sample using the proofreading DNA polymerase KOD-Plus-Neo (Toyobo) (Figure <xref ref-type="media" rid="MOESM1">S1</xref>). The forward primer 5′-AATCCCAAGCTTCACCATGTACTTCATGAACATCACGTGGGAT-3′ carried a <italic>Hin</italic>dIII restriction site at the 3′-end, whereas the reverse primer 5′-GCCTAGTCTAGATCACTCCCCGATCATGCCGTT-3′ had a stop codon and an <italic>Xba</italic>I restriction site at the 5′-end.</p>
</sec>
<sec id="Sec8">
<title>Cell culture and transfection</title>
<p id="Par12">Dulbecco’s minimum essential medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Sigma-Aldrich) were used for culturing HEK 293 cells. Cells were plated in 3.5-mm dishes 1 day before the transfection and were transfected with 1 μg minigene construct using FuGENE 6 (Roche) by following the standard method. Forty-eight hours after the transfection, we performed reverse transcription polymerase chain reaction (RT-PCR) for the cells.</p>
</sec>
<sec id="Sec9">
<title>RNA extraction and RT-PCR</title>
<p id="Par13">RNeasy Mini Kit (Qiagen) was used to extract total RNA according to the custom methods. Then we synthesized cDNA by using ReverTra Ace reverse transcriptase (Toyobo). GoTaq polymerase (Promega) were used to perform PCR with forward primer designed from exon 4 of <italic>GRIN2D</italic> (5′-CTTCATGAACATCACGTGGG-3′) and reverse primer from exon 6 (5′-GAGTGGCACCTTCCAGGGTC-3′) (Figure <xref ref-type="media" rid="MOESM1">S1</xref>). Then, we performed agarose gel electrophoresis of PCR products. The correct size bands were excised from the gel by using PCR Cleanup System (Promega) and Wizard<sup>®</sup> SV Gel and sequenced using Sanger method to confirm the sequence of every band (Fig. <xref ref-type="fig" rid="Fig1">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Mutant <italic>GRIN2D</italic> caused intron 5 inclusion</p></caption><graphic id="d29e3705" xlink:href="41398_2017_61_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec10">
<title>Follow-up analysis</title>
<p id="Par14">The statistical power of effective sample size was processed with website program, Genetic Power Calculator (<ext-link ext-link-type="uri" xlink:href="http://zzz.bwh.harvard.edu/gpc/">http://zzz.bwh.harvard.edu/gpc/</ext-link>)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. With the following parameters: risk rare-allele frequency (A) of 0.01, disease prevalence of 0.01, genotype relative risk (Aa) ≥ 2, genotype relative risk (AA) ≥ 4, marker allele frequency (B) of 0.01, number of cases (<italic>n</italic> = 2259) and controls (<italic>n </italic>= 2040), and type I error rate of 0.05, we computed the result that our sample size have a statistical power of &gt;80%. Only sequences resulting in possible LoF mutations were selected for genotyping. These included one novel frameshift and one novel splice site mutation. Genotyping of the frameshift mutation was performed using a probe oligo that was designed by and ordered from SIGMA-DLP. Genotyping of the splice site mutation was performed with a probe primer (Thermo Fisher Scientific) and Taqman (Applied Biosystems) standard probes. The 384-well microtiter plates were used for analysis, and every plate contained at least one sample carrying confirmed variant and one non-template control. ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) was used for the following analysis with standard method. Then, we compared the mutations with differences allele and genotype frequencies between patients and controls.</p>
</sec>
</sec>
<sec id="Sec11" sec-type="results">
<title>Results</title>
<sec id="Sec12">
<title>Results of mutation screening</title>
<p id="Par15">Our sequence data is available with the accession number DRA004490DNA in the Data Bank of Japan databases (<ext-link ext-link-type="uri" xlink:href="http://www.ddbj.nig.ac.jp">http://www.ddbj.nig.ac.jp</ext-link>). Resequencing of the <italic>GRIN1</italic>, <italic>GRIN2A</italic>, <italic>GRIN2C</italic>,<italic> GRIN2D</italic>,<italic> GRIN3A</italic>, and <italic>GRIN3B</italic> coding regions using Ion PGM platform identified 40 rare (minor allele frequency &lt; 1%), nonsynonymous mutations, including 38 missense mutations, one frameshift mutation with 4 bp deletion (P132Fs in <italic>GRIN2C</italic>), and one splice site mutation (c.1412G &gt; A in <italic>GRIN2D</italic>). All mutations were confirmed by using the Sanger method, and all of them were heterozygous. Among them, 10 variants had available DNA for both of their parents. All the 10 variants were then identified to be inherited by Sanger sequencing, and no de novo variants were found. We searched five genetic databases (dbSNP build 143, 1000 Genomes Project, ExAC, HGVD, and iJGVD) and identified eight variants to be novel variants including the two LoF mutations (P132Fs in <italic>GRIN2C</italic> and c.1412G &gt; A in <italic>GRIN2D</italic>). Then, we conducted in silico analysis for the 40 variants and detected 7 missense variants with deleterious prediction in all of the in silico tools we used (SIFT, PolyPhen-2, MUTATIONTASTER). The details and bioinformatics analysis of all 40 mutations are shown in Table <xref ref-type="table" rid="Tab2">2</xref>.</p>
</sec>
<sec id="Sec13">
<title>Results of splice site mutation</title>
<p id="Par16">The splice site mutation c.1412G &gt; A-<italic>GRIN2D</italic> revealed a novel G-to-A transition (NM_000836.2: c.1412G &gt; A) at the last nucleotide of exon 5. The predicted results due to splicing according to in silico tools were as follows: SD-Score<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> predicted c.1412G &gt; A-<italic>GRIN2D</italic> to be aberrant, the human splicing finder<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> predicted the variant to most probably affect the splicing, and maximum entropy modeling (MaxEntScan)<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> assigned the mutation a score of −1.87 points, whereas the normal sequence had a score of 5.49 points (Table <xref ref-type="table" rid="Tab3">3</xref>). Then, we performed a functional splicing reporter minigene assay. In Fig. <xref ref-type="fig" rid="Fig1">1</xref>, the image shows the resequencing results of the RT-PCR products. Highest bind from the mutant confirmed to containing exon 4 (114 bp), part of intron 4 (99 bp), exon 5 (212 bp), intron 5 (267 bp), and exon 6 (169 bp); second bind from mutant and wild type (WT) containing exon 4 (114 bp), exon 5 (212 bp), intron 5 (267 bp), and exon 6 (169 bp); lowest bind from WT containing exon 4 (114 bp), exon 5 (212 bp), and exon 6 (169 bp). Thus, we confirmed an intron 5 retention due to the mutation, which result in meeting premature stop codon (Figure <xref ref-type="media" rid="MOESM1">S2</xref>). As normal <italic>GRIN2D</italic> were confirmed to have only one isoform (NM_000836.2), we surmise that c.1412G&gt;A-<italic>GRIN2D</italic> will lead to a truncated, incomplete protein product.</p>
</sec>
<sec id="Sec14">
<title>Results of further genotyping</title>
<p id="Par17">Frameshift mutation P132Fs in <italic>GRIN2C</italic> and splice site mutation c.1412G&gt;A in <italic>GRIN2D</italic> were selected for genotyping in an larger sample set which included 1877 SCZ cases, 382 ASD cases, and 2040 controls for association analysis. The result showed that no mutations were found in the sample set used for genotyping (Table <xref ref-type="table" rid="Tab4">4</xref>). Importantly, both mutations, P132Fs in <italic>GRIN2C</italic> and c.1412G&gt;A in <italic>GRIN2D</italic>, were only present in a single case, not only among 2821 cases and 2040 controls in this study but also never seen in the following databases: dbSNP build 143, 1000 Genomes Project, ExAC, HGVD, and iJGVD. Thus, we considered them as protein-damaging ultra-rare variants.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Association analysis results of two loss-of-function mutations</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variant</th><th colspan="2">Genotype counts (resequencing)</th><th colspan="3">Genotype counts (association)</th><th colspan="2">
<italic>P</italic> value</th></tr><tr><th></th><th>SCZ</th><th>ASD</th><th>SCZ</th><th>ASD</th><th>Control</th><th>SCZ</th><th>ASD</th></tr></thead><tbody><tr><td>GRIN2C-P132fs</td><td>0/1/739</td><td>0/0/384</td><td>0/0/3576</td><td>0/0/384</td><td>0/0/4080</td><td>–</td><td>–</td></tr><tr><td>GRIN2D-c.1412G&gt;A</td><td>0/1/739</td><td>0/0/384</td><td>0/0/3576</td><td>0/0/384</td><td>0/0/4080</td><td>–</td><td>–</td></tr></tbody></table><table-wrap-foot><p>Genotype counts: Homozygote of minor allele/heterozygote/homozygote of major allele</p></table-wrap-foot></table-wrap>
</p>
</sec>
</sec>
<sec id="Sec15" sec-type="discussion">
<title>Discussion</title>
<p id="Par18">We performed a systematic work of sequencing the coding regions of NMDARs genes in SCZ and ASD, and detected 40 rare, nonsynonymous mutations in this study. Among them, two LoF mutations in two patients suffering from SCZ were identified: one frameshift mutation (P132Fs in <italic>GRIN2C</italic>) and one splice site mutation (with intron retaining) (c.1412G&gt;A in <italic>GRIN2D</italic>). P132Fs in <italic>GRIN2C</italic> was located in the beginning of the sequence (Figure <xref ref-type="media" rid="MOESM1">S3</xref>), the 4 bp deletion creating a premature stop codon (p.P132FsX192). Another mutation was c.1412G&gt;A in <italic>GRIN2D</italic>, with a G-to-A transition in the last nucleotide of exon 5. Minigene assay confirmed that this mutation resulted in intron 5 retention carrying two stop codons (Figure <xref ref-type="media" rid="MOESM1">S2</xref>), which may lead to the introduction of premature termination codons, and possibly causing nonfunctional NR2D receptor to be created. Notably, frameshift mutations in some genes, such as <italic>DISC1</italic>
<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>,<italic> NLGN4</italic>
<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>, and <italic>UPF3B</italic>
<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>, were identified in SCZ and/or ASD patients, suggesting that frameshift mutations may increase susceptibility to SCZ and ASD. Other studies associate intron retention with the pathogenesis of SCZ<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> and other genetic disorders, such as familial partial lipodystrophy type 2 (ref. <xref ref-type="bibr" rid="CR45">45</xref>) and limb girdle muscular dystrophy type 1B<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, which suggested a role for intron retention in the development of genetic disorders. LoF mutations were often assumed to confer greater disease susceptibility than other missense mutations due to disruption of gene or protein function<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. They were identified as having an increased contribution to SCZ and ASD, especially in functional sets that are closely involved in neurodevelopment<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Genome-wide significant association has also been identified between rare LoF mutations and risk for SCZ and other developmental disorders<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. However, it cannot be ignored that LoF variants were detected also in healthy adults<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup> with surprisingly no deleterious consequences.</p>
<p id="Par19">Furthermore, we conducted association analysis for P132Fs in <italic>GRIN2C</italic> and c.1412G&gt;A in <italic>GRIN2D</italic>. Both of the two variants are singleton among 2259 cases and 2040 controls, and also have never been noted in the following databases (dbSNP build 143, 1000 Genomes Project, ExAC, HGVD, and iJGVD), which indicated them to be ultra-rare variants. As LoF ultra-rare variants are suggested to be more abundant among cases with psychiatry disorders than controls<sup><xref ref-type="bibr" rid="CR49">49</xref>–<xref ref-type="bibr" rid="CR51">51</xref></sup>, the two mutations may confer a strong genetic influence on SCZ risk.</p>
<p id="Par20">In addition to LoF mutations, we also identified 38 missense mutations in SCZ/ASD patients in <italic>GRIN1</italic>,<italic> GRIN2A</italic>,<italic> GRIN2C</italic>,<italic> GRIN2D</italic>, <italic>GRIN3A</italic>, and <italic>GRIN3B</italic>. Among them, six missense mutations were ultra-rare variants. Seven mutations are predicted to be disruptive using all the three in silico tools we used (SIFT, PolyPhen-2, MUTATIONTASTER). Although in silico predictions are questionable, they are still irreplaceable and used widely to predict the impact of missense variants<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. Moreover, two missense mutations in <italic>GRIN2A</italic> (K441N, K590N) and one missense mutation in <italic>GRIN2C</italic> (E514K) are observed to be positioned on glutamate-binding domain, which is highly conserved in primate. Some studies gave the possibility that the ligand-binding regions were more likely to be disruptive than in other domains<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, which also indicate the importance of ligand-binding domain.</p>
<p id="Par21">There are several limitations of our study that should not be ignored. First, we only sequenced the coding region of <italic>GRIN1</italic>, <italic>GRIN2A</italic>,<italic> GRIN2C</italic>,<italic> GRIN2D</italic>,<italic> GRIN3A</italic>, and <italic>GRIN3B</italic>. We excluded promoter, intronic, and 5′- and 3′-untranslated regions. Second, in the genotyping analysis, no statistical significance were in our study, it may be because the size of our samples had no sufficient power. Future studies should include a larger sample size to identify a wider range of rare mutations. Third, due to the difficulty of collecting samples of family members, we were only able to do pedigree analysis for a few subjects. Fourth, to avoid ambiguous pathogenicity interpretations, we excluded missense variants from the association analysis. This strict exclusion criterion limits the number of potential confounding factors, which may cause potentially important targets to be missed.</p>
<p id="Par22">In conclusion, we revealed 40 rare variants including 38 missense mutations, one frameshift mutation, and one splice site mutation by screening the exonic regions of <italic>GRIN1</italic>, <italic>GRIN2A</italic>, <italic>GRIN2C</italic>, <italic>GRIN2D</italic>, <italic>GRIN3A</italic>, and <italic>GRIN3B</italic>. Our result might imply that these mutations increase susceptibility to SCZ and ASD. Furthermore, the observation of the two LoF mutations in <italic>GRIN2C</italic> and <italic>GRIN2D</italic> supports the hypothesis that an increased burden of ultra-rare deleterious mutations could be observed in SCZ, although statistical significance was not obtained in association analysis. In addition, our data also gave more evidences to support the likely role of NMDARs in SCZ and ASD with a neurodevelopmental origin.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Electronic supplementary material</title>
<sec id="Sec16">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41398_2017_61_MOESM1_ESM.docx"><caption><p>Supplementary Materials</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher's note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>
<bold>Supplementary information</bold>
</p>
<p>The online version of this article (doi:10.1038/s41398-017-0061-y) contains supplementary material.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>The present study was supported by research grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and the Ministry of Health, Labor, and Welfare of Japan.</p>
</ack>
<notes notes-type="COI-statement">
<sec id="FPar1">
<title>Competing interests</title>
<p id="Par23">The authors declare that they have no competing financial interests.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandin</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The familial risk of autism</article-title>
<source/>JAMA
          <year>2014</year>
<volume>311</volume>
<fpage>1770</fpage>
<lpage>1777</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2014.4144</pub-id>
<pub-id pub-id-type="pmid">24794370</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giusti-Rodriguez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>The genomics of schizophrenia: update and implications</article-title>
<source/>J. Clin. Invest.
          <year>2013</year>
<volume>123</volume>
<fpage>4557</fpage>
<lpage>4563</lpage>
<pub-id pub-id-type="doi">10.1172/JCI66031</pub-id>
<pub-id pub-id-type="pmid">24177465</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loohuis</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide burden of deleterious coding variants increased in schizophrenia</article-title>
<source/>Nat. Commun.
          <year>2015</year>
<volume>6</volume>
<fpage>7501</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms8501</pub-id>
<pub-id pub-id-type="pmid">26158538</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Kendler</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2003</year>
<volume>60</volume>
<fpage>1187</fpage>
<lpage>1192</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.60.12.1187</pub-id>
<pub-id pub-id-type="pmid">14662550</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Autism</article-title>
<source/>Lancet
          <year>2014</year>
<volume>383</volume>
<fpage>896</fpage>
<lpage>910</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(13)61539-1</pub-id>
<pub-id pub-id-type="pmid">24074734</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colvert</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heritability of autism spectrum disorder in a UK population-based twin sample</article-title>
<source/>JAMA Psychiatry
          <year>2015</year>
<volume>72</volume>
<fpage>415</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.3028</pub-id>
<pub-id pub-id-type="pmid">25738232</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paoletti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bellone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2013</year>
<volume>14</volume>
<fpage>383</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3504</pub-id>
<pub-id pub-id-type="pmid">23686171</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papenberg</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dopamine and glutamate receptor genes interactively influence episodic memory in old age</article-title>
<source/>Neurobiol. Aging
          <year>2014</year>
<volume>35</volume>
<fpage>e1213</fpage>
<lpage>e1218</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.11.014</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>KB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structural determinants of agonist efficacy at the glutamate binding site of <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors</article-title>
<source/>Mol. Pharmacol.
          <year>2013</year>
<volume>84</volume>
<fpage>114</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1124/mol.113.085803</pub-id>
<pub-id pub-id-type="pmid">23625947</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meador-Woodruff</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Clinton</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Beneyto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McCullumsmith</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia</article-title>
<source/>Ann. NY Acad. Sci.
          <year>2003</year>
<volume>1003</volume>
<fpage>75</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1300.005</pub-id>
<pub-id pub-id-type="pmid">14684436</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayser</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Dalmau</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Anti-NMDA receptor encephalitis, autoimmunity, and psychosis</article-title>
<source/>Schizophr. Res.
          <year>2016</year>
<volume>176</volume>
<fpage>36</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2014.10.007</pub-id>
<pub-id pub-id-type="pmid">25458857</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belforte</surname>
<given-names>JE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes</article-title>
<source/>Nat. Neurosci.
          <year>2010</year>
<volume>13</volume>
<fpage>76</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2447</pub-id>
<pub-id pub-id-type="pmid">19915563</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity</article-title>
<source/>Science
          <year>2004</year>
<volume>304</volume>
<fpage>1021</fpage>
<lpage>1024</lpage>
<pub-id pub-id-type="doi">10.1126/science.1096615</pub-id>
<pub-id pub-id-type="pmid">15143284</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cull-Candy</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Leszkiewicz</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Role of distinct NMDA receptor subtypes at central synapses</article-title>
<source/>Sci. STKE
          <year>2004</year>
<volume>2004</volume>
<fpage>re16</fpage>
<pub-id pub-id-type="pmid">15494561</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itokawa</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A microsatellite repeat in the promoter of the <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia</article-title>
<source/>Pharmacogenetics
          <year>2003</year>
<volume>13</volume>
<fpage>271</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1097/00008571-200305000-00006</pub-id>
<pub-id pub-id-type="pmid">12724619</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnby</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT</article-title>
<source/>Am. J. Hum. Genet.
          <year>2005</year>
<volume>76</volume>
<fpage>950</fpage>
<lpage>966</lpage>
<pub-id pub-id-type="doi">10.1086/430454</pub-id>
<pub-id pub-id-type="pmid">15830322</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gai</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare structural variation of synapse and neurotransmission genes in autism</article-title>
<source/>Mol. Psychiatry
          <year>2012</year>
<volume>17</volume>
<fpage>402</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2011.10</pub-id>
<pub-id pub-id-type="pmid">21358714</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forero</surname>
<given-names>DA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A network of synaptic genes associated with schizophrenia and bipolar disorder</article-title>
<source/>Schizophr. Res.
          <year>2016</year>
<volume>172</volume>
<fpage>68</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2016.02.012</pub-id>
<pub-id pub-id-type="pmid">26899345</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarabeux</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare mutations in <italic>N</italic>-methyl-<sc>d</sc>-aspartate glutamate receptors in autism spectrum disorders and schizophrenia</article-title>
<source/>Transl. Psychiatry
          <year>2011</year>
<volume>1</volume>
<fpage>e55</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2011.52</pub-id>
<pub-id pub-id-type="pmid">22833210</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<mixed-citation publication-type="other">Perez-Palma, E. <italic>et al</italic>. Duplications at 19q13. 33 in patients with neurodevelopmental disorders. <italic>bioRxiv</italic> 130377 (2017).</mixed-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>YT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A recently-discovered NMDA receptor gene, GRIN3B, is associated with duration mismatch negativity</article-title>
<source/>Psychiatry Res.
          <year>2014</year>
<volume>218</volume>
<fpage>356</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2014.04.032</pub-id>
<pub-id pub-id-type="pmid">24814139</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sprengel</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo</article-title>
<source/>Cell
          <year>1998</year>
<volume>92</volume>
<fpage>279</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80921-6</pub-id>
<pub-id pub-id-type="pmid">9458051</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hillman</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Stairs</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Buonanno</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dravid</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory</article-title>
<source/>Neurobiol. Learn. Mem.
          <year>2011</year>
<volume>95</volume>
<fpage>404</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1016/j.nlm.2011.01.008</pub-id>
<pub-id pub-id-type="pmid">21295149</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perszyk</surname>
<given-names>RE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GluN2D-containing <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptors mediate synaptic transmission in hippocampal interneurons and regulate interneuron activity</article-title>
<source/>Mol. Pharmacol.
          <year>2016</year>
<volume>90</volume>
<fpage>689</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1124/mol.116.105130</pub-id>
<pub-id pub-id-type="pmid">27625038</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chuang</surname>
<given-names>YA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare mutations and hypermethylation of the ARC gene associated with schizophrenia</article-title>
<source/>Schizophr. Res.
          <year>2016</year>
<volume>176</volume>
<fpage>106</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2016.07.019</pub-id>
<pub-id pub-id-type="pmid">27464451</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders</article-title>
<source/>Nat. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>571</fpage>
<lpage>577</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4267</pub-id>
<pub-id pub-id-type="pmid">26974950</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flint</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Rare genetic variants and schizophrenia</article-title>
<source/>Nat. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>525</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4271</pub-id>
<pub-id pub-id-type="pmid">27021940</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacArthur</surname>
<given-names>DG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A systematic survey of loss-of-function variants in human protein-coding genes</article-title>
<source/>Science
          <year>2012</year>
<volume>335</volume>
<fpage>823</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="doi">10.1126/science.1215040</pub-id>
<pub-id pub-id-type="pmid">22344438</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kataoka</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing for bipolar disorder points to roles of de novo loss-of-function and protein-altering mutations</article-title>
<source/>Mol. Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>885</fpage>
<lpage>893</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2016.69</pub-id>
<pub-id pub-id-type="pmid">27217147</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genovese</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia</article-title>
<source/>Nat. Neurosci.
          <year>2016</year>
<volume>19</volume>
<fpage>1433</fpage>
<lpage>1441</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4402</pub-id>
<pub-id pub-id-type="pmid">27694994</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takasaki</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation screening of GRIN2B in schizophrenia and autism spectrum disorder in a Japanese population</article-title>
<source/>Sci. Rep.
          <year>2016</year>
<volume>6</volume>
<fpage>33311</fpage>
<pub-id pub-id-type="doi">10.1038/srep33311</pub-id>
<pub-id pub-id-type="pmid">27616045</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adzhubei</surname>
<given-names>IA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A method and server for predicting damaging missense mutations</article-title>
<source/>Nat. Methods
          <year>2010</year>
<volume>7</volume>
<fpage>248</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id>
<pub-id pub-id-type="pmid">20354512</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Henikoff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm</article-title>
<source/>Nat. Protoc.
          <year>2009</year>
<volume>4</volume>
<fpage>1073</fpage>
<lpage>1081</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2009.86</pub-id>
<pub-id pub-id-type="pmid">19561590</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwarz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Schuelke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seelow</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>MutationTaster2: mutation prediction for the deep-sequencing age</article-title>
<source/>Nat. Methods
          <year>2014</year>
<volume>11</volume>
<fpage>361</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1038/nmeth.2890</pub-id>
<pub-id pub-id-type="pmid">24681721</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kircher</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>
<source/>Nat. Genet.
          <year>2014</year>
<volume>46</volume>
<fpage>310</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2892</pub-id>
<pub-id pub-id-type="pmid">24487276</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahashi</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5’ splice sites</article-title>
<source/>Nucleic Acids Res.
          <year>2007</year>
<volume>35</volume>
<fpage>5995</fpage>
<lpage>6003</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkm647</pub-id>
<pub-id pub-id-type="pmid">17726045</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>TA</given-names>
</name>
</person-group>
<article-title>Splicing in disease: disruption of the splicing code and the decoding machinery</article-title>
<source/>Nat. Rev. Genet.
          <year>2007</year>
<volume>8</volume>
<fpage>749</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2164</pub-id>
<pub-id pub-id-type="pmid">17726481</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Burge</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals</article-title>
<source/>J. Comput. Biol.
          <year>2004</year>
<volume>11</volume>
<fpage>377</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="doi">10.1089/1066527041410418</pub-id>
<pub-id pub-id-type="pmid">15285897</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Purcell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cherny</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Sham</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits</article-title>
<source/>Bioinformatics
          <year>2003</year>
<volume>19</volume>
<fpage>149</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/19.1.149</pub-id>
<pub-id pub-id-type="pmid">12499305</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desmet</surname>
<given-names>FO</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human Splicing Finder: an online bioinformatics tool to predict splicing signals</article-title>
<source/>Nucleic Acids Res.
          <year>2009</year>
<volume>37</volume>
<fpage>e67</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkp215</pub-id>
<pub-id pub-id-type="pmid">19339519</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sachs</surname>
<given-names>NA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder</article-title>
<source/>Mol. Psychiatry
          <year>2005</year>
<volume>10</volume>
<fpage>758</fpage>
<lpage>764</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001667</pub-id>
<pub-id pub-id-type="pmid">15940305</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients</article-title>
<source/>Mol. Psychiatry
          <year>2005</year>
<volume>10</volume>
<fpage>329</fpage>
<lpage>332</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001629</pub-id>
<pub-id pub-id-type="pmid">15622415</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Addington</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel frameshift mutation in UPF3B identified in brothers affected with childhood onset schizophrenia and autism spectrum disorders</article-title>
<source/>Mol. Psychiatry
          <year>2011</year>
<volume>16</volume>
<fpage>238</fpage>
<pub-id pub-id-type="doi">10.1038/mp.2010.59</pub-id>
<pub-id pub-id-type="pmid">20479756</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faul</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ZDHHC8 as a candidate gene for schizophrenia: analysis of a putative functional intronic marker in case–control and family-based association studies</article-title>
<source/>BMC Psychiatry
          <year>2005</year>
<volume>5</volume>
<fpage>35</fpage>
<pub-id pub-id-type="doi">10.1186/1471-244X-5-35</pub-id>
<pub-id pub-id-type="pmid">16225675</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morel</surname>
<given-names>CF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2</article-title>
<source/>J. Clin. Endocrinol. Metab.
          <year>2006</year>
<volume>91</volume>
<fpage>2689</fpage>
<lpage>2695</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2005-2746</pub-id>
<pub-id pub-id-type="pmid">16636128</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muchir</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B)</article-title>
<source/>Hum. Mol. Genet.
          <year>2000</year>
<volume>9</volume>
<fpage>1453</fpage>
<lpage>1459</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/9.9.1453</pub-id>
<pub-id pub-id-type="pmid">10814726</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgess</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Human genetics: loss-of-function variants—not always what they seem</article-title>
<source/>Nat. Rev. Genet.
          <year>2016</year>
<volume>17</volume>
<fpage>251</fpage>
<pub-id pub-id-type="doi">10.1038/nrg.2016.33</pub-id>
<pub-id pub-id-type="pmid">26972591</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narasimhan</surname>
<given-names>VM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Health and population effects of rare gene knockouts in adult humans with related parents</article-title>
<source/>Science
          <year>2016</year>
<volume>352</volume>
<fpage>474</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1126/science.aac8624</pub-id>
<pub-id pub-id-type="pmid">26940866</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<mixed-citation publication-type="other">Genovese, G. <italic>et al</italic>. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. <italic>Nat. Neurosci</italic>. <bold>2016</bold>, 1433–1441 (2016).</mixed-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of high risk DISC1 protein structural variants in patients with bipolar spectrum disorder</article-title>
<source/>Neurosci. Lett.
          <year>2010</year>
<volume>486</volume>
<fpage>136</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.09.027</pub-id>
<pub-id pub-id-type="pmid">20850505</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>Epi Kc and Epilepsy Phenome/Genome P.</collab>
</person-group>
<article-title>Ultra-rare genetic variation in common epilepsies: a case–control sequencing study</article-title>
<source/>Lancet Neurol.
          <year>2017</year>
<volume>16</volume>
<fpage>135</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)30359-3</pub-id>
<pub-id pub-id-type="pmid">28102150</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies</article-title>
<source/>Hum. Mol. Genet.
          <year>2015</year>
<volume>24</volume>
<fpage>2125</fpage>
<lpage>2137</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu733</pub-id>
<pub-id pub-id-type="pmid">25552646</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ionita-Laza</surname>
<given-names>I</given-names>
</name>
<name>
<surname>McCallum</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>A spectral approach integrating functional genomic annotations for coding and noncoding variants</article-title>
<source/>Nat. Genet.
          <year>2016</year>
<volume>48</volume>
<fpage>214</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3477</pub-id>
<pub-id pub-id-type="pmid">26727659</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burnashev</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Szepetowski</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>NMDA receptor subunit mutations in neurodevelopmental disorders</article-title>
<source/>Curr. Opin. Pharmacol.
          <year>2015</year>
<volume>20</volume>
<fpage>73</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.coph.2014.11.008</pub-id>
<pub-id pub-id-type="pmid">25498981</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>